Thrombotic thrombocytopenic purpura and gemcitabine

Pashtoon Murtaza Kasi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening complication of gemcitabine treatment. Since the approval of this nucleoside analog for the treatment of pancreatic cancer by the FDA in 1996, reported incidence varies from 0.015 to 1.4%. The classic 'pentad' describing the disease process (fever, hemolytic anemia, thrombocytopenia, neurological complications and renal impairment) is not always present to the same extent in every patient. Here, we present a rare case of TTP associated specifically with gemcitabine treatment, and further, we briefly discuss the manifestations, treatment options and outcomes related to the complication. In our opinion, it is important to realize that as the indications for the use of gemcitabine increase and its use becomes more widespread, TTP and other disorders on the spectrum of thrombotic microangiopathies are important considerations to remember in patients with worsening anemia and thrombocytopenia. New onset or exacerbation of underlying hypertension may provide a clue to diagnose the disease entity earlier in this subgroup of patients.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalCase Reports in Oncology
Volume4
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

gemcitabine
Thrombotic Thrombocytopenic Purpura
Thrombocytopenia
Thrombotic Microangiopathies
Hemolytic Anemia
Pancreatic Neoplasms
Nucleosides
Anemia
Fever
Therapeutics
Hypertension
Kidney
Incidence

Keywords

  • Gemcitabine
  • Non-small cell lung cancer
  • Thrombotic thrombocytopenic purpura

ASJC Scopus subject areas

  • Oncology

Cite this

Thrombotic thrombocytopenic purpura and gemcitabine. / Kasi, Pashtoon Murtaza.

In: Case Reports in Oncology, Vol. 4, No. 1, 01.2011, p. 143-148.

Research output: Contribution to journalArticle

Kasi, Pashtoon Murtaza. / Thrombotic thrombocytopenic purpura and gemcitabine. In: Case Reports in Oncology. 2011 ; Vol. 4, No. 1. pp. 143-148.
@article{c8a96cf520b7455194942d0a9bfc43e4,
title = "Thrombotic thrombocytopenic purpura and gemcitabine",
abstract = "Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening complication of gemcitabine treatment. Since the approval of this nucleoside analog for the treatment of pancreatic cancer by the FDA in 1996, reported incidence varies from 0.015 to 1.4{\%}. The classic 'pentad' describing the disease process (fever, hemolytic anemia, thrombocytopenia, neurological complications and renal impairment) is not always present to the same extent in every patient. Here, we present a rare case of TTP associated specifically with gemcitabine treatment, and further, we briefly discuss the manifestations, treatment options and outcomes related to the complication. In our opinion, it is important to realize that as the indications for the use of gemcitabine increase and its use becomes more widespread, TTP and other disorders on the spectrum of thrombotic microangiopathies are important considerations to remember in patients with worsening anemia and thrombocytopenia. New onset or exacerbation of underlying hypertension may provide a clue to diagnose the disease entity earlier in this subgroup of patients.",
keywords = "Gemcitabine, Non-small cell lung cancer, Thrombotic thrombocytopenic purpura",
author = "Kasi, {Pashtoon Murtaza}",
year = "2011",
month = "1",
doi = "10.1159/000326801",
language = "English (US)",
volume = "4",
pages = "143--148",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

TY - JOUR

T1 - Thrombotic thrombocytopenic purpura and gemcitabine

AU - Kasi, Pashtoon Murtaza

PY - 2011/1

Y1 - 2011/1

N2 - Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening complication of gemcitabine treatment. Since the approval of this nucleoside analog for the treatment of pancreatic cancer by the FDA in 1996, reported incidence varies from 0.015 to 1.4%. The classic 'pentad' describing the disease process (fever, hemolytic anemia, thrombocytopenia, neurological complications and renal impairment) is not always present to the same extent in every patient. Here, we present a rare case of TTP associated specifically with gemcitabine treatment, and further, we briefly discuss the manifestations, treatment options and outcomes related to the complication. In our opinion, it is important to realize that as the indications for the use of gemcitabine increase and its use becomes more widespread, TTP and other disorders on the spectrum of thrombotic microangiopathies are important considerations to remember in patients with worsening anemia and thrombocytopenia. New onset or exacerbation of underlying hypertension may provide a clue to diagnose the disease entity earlier in this subgroup of patients.

AB - Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening complication of gemcitabine treatment. Since the approval of this nucleoside analog for the treatment of pancreatic cancer by the FDA in 1996, reported incidence varies from 0.015 to 1.4%. The classic 'pentad' describing the disease process (fever, hemolytic anemia, thrombocytopenia, neurological complications and renal impairment) is not always present to the same extent in every patient. Here, we present a rare case of TTP associated specifically with gemcitabine treatment, and further, we briefly discuss the manifestations, treatment options and outcomes related to the complication. In our opinion, it is important to realize that as the indications for the use of gemcitabine increase and its use becomes more widespread, TTP and other disorders on the spectrum of thrombotic microangiopathies are important considerations to remember in patients with worsening anemia and thrombocytopenia. New onset or exacerbation of underlying hypertension may provide a clue to diagnose the disease entity earlier in this subgroup of patients.

KW - Gemcitabine

KW - Non-small cell lung cancer

KW - Thrombotic thrombocytopenic purpura

UR - http://www.scopus.com/inward/record.url?scp=79957615149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957615149&partnerID=8YFLogxK

U2 - 10.1159/000326801

DO - 10.1159/000326801

M3 - Article

C2 - 21691573

AN - SCOPUS:79957615149

VL - 4

SP - 143

EP - 148

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -